98%
921
2 minutes
20
: bLH is considered an excellent biochemical predictor of CPP. However, its utilization in clinical practice shows some uncertainties. This study aims to evaluate the diagnostic power of bLH and propose a diagnostic algorithm for CPP. : We conducted a monocentric cohort retrospective study evaluating all females referred for suspicion of CPP between 1 January 2017 and 31 December 2020 who underwent a GnRH test. Auxological, hormonal, and instrumental data were collected, including pelvic ultrasonography and bone age (BA) assessment. Simple linear regression, -test, and ROC tests were utilized to study the diagnostic value of basal hormone levels. Two hundred thirteen girls were included in the study. They were subdivided into two groups according to the results of the GnRH test: Group 1, with LH peak > 5 IU/L (pubertal) and 79 patients (37%), and Group 2, with an LH peak ≤ 5 IU/L (prepubertal) and 134 patients (63%). : The ROC curve showed that bLH level > 1.5 Ul/L best predicts a pubertal response to the GnRH test (AUC 0.8821, accuracy 82%), with low sensitivity (34%). The multivariate analysis found that bLH > 0.5 IU/L, basal FSH (bFSH) > 3.5 IU/L, bLH/bFSH ratio > 0.16, BA advancement > 1.7 years, uterine volume > 3.6 mL, longitudinal uterine diameter > 41 mm, and the presence of endometrial rhyme were significantly associated with a pubertal response at the GnRH test. An algorithm based on these features was created, and its application would reduce the number of GnRH tests by 34%. Overall, 96.2% of Group 1 patients reached the LH peak at the 30th minute of the GnRH test, supporting the hypothesis that the GnRH test duration could be reduced to 30 min. : Morning bLH > 1.5 IU/L could be carefully used as a diagnostic predictor of CPP. The GnRH test, even reduced to 30 min, could be reserved for girls who show low intermediate morning bLH and specific clinical signs of pubertal development.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10972438 | PMC |
http://dx.doi.org/10.3390/medicina60030497 | DOI Listing |
Stem Cell Rev Rep
September 2025
Stem Cells and Metabolism Research Program (STEMM), Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, 00014, Finland.
Mutations in Delta Like Non-Canonical Notch Ligand 1 (DLK1), a paternally expressed imprinted gene, underlie central precocious puberty (CPP), yet the mechanism remains unclear. To test the hypothesis that DLK1 plays a role in gonadotropin releasing hormone (GnRH) neuron ontogeny, 75 base pairs were deleted in both alleles of DLK1 exon 3 with CRISPR-Cas9 in human pluripotent stem cells (hPSCs). This line, exhibiting More than 80% loss of DLK1 protein, was differentiated into GnRH neurons by dual SMAD inhibition (dSMADi), FGF8 treatment and Notch inhibition, as previously described, however, it did not exhibit accelerated GNRH1 expression.
View Article and Find Full Text PDFFront Pediatr
August 2025
Department of Pediatrics, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China.
Background: Body mass index (BMI) may influence peak luteinizing hormone (PLH) levels during gonadotropin releasing hormone (GnRH) or GnRH analogues stimulation testing. BMI effects should be considered when interpreting test results for pubertal disorders in girls with overweight/obesity, but few studies have excluded it.
Methods: This was a hospital data-based retrospective study.
Womens Health (Lond)
September 2025
Worldwide Medical and Safety, Pfizer Inc, New York, NY, USA.
Background: Endometriosis symptoms have multifaceted manifestations, and there are few approved nonsurgical treatment options. Gonadotropin-releasing hormone (GnRH) agonists/antagonists for endometriosis vary on efficacy, safety profile, and out-of-pocket (OOP) cost, among other features.
Objectives: This study quantified the importance that women with endometriosis in the United States (US) placed on pain and non-pain features that differ among these medications.
Eur J Obstet Gynecol Reprod Biol
September 2025
Department of Obstetrics and Gynaecology, University of Medicine and Pharmacy at Ho Chi Minh City, Vietnam.
Research Question: Does progestin-primed ovarian stimulation (PPOS) using dydrogesterone yield a live birth rate comparable with the gonadotrophin-releasing hormone (GnRH) antagonist protocol in in-vitro fertilization (IVF) freeze-all cycles?
Design: This retrospective cohort study, conducted at a tertiary hospital from June 2022 to January 2024, included 1045 women aged 18-40 years undergoing IVF/intracytoplasmic sperm injection with freeze-all indications. Participants were assigned to receive PPOS-dydrogesterone (n = 482) or GnRH antagonist (n = 563), followed by frozen embryo transfer (FET). The primary outcome was the live birth rate after the first FET cycle.
Comput Struct Biotechnol J
August 2025
Department of Obstetrics, Gynecology and Reproductive Medicine, Foch Hospital, Suresnes, France.
Background: The dynamic interplay of ovarian hormones is central to reproductive physiology, yet the complexity of their cyclic variations poses challenges for analysis, simulation, and teaching. This study presents a framework for generating physiologically constrained, multi-hormone synthetic time series that capture intra- and inter-individual variability across phenotypes.
Methods: We developed a semi-mechanistic mathematical framework to generate synthetic multi-hormone profiles (estradiol, FSH, LH, AMH, testosterone, GnRH) using parametric equations embedding known physiological feedbacks (e.